Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Stryker is a leading medical technology company with operations in Orthopaedic Implants and MedSurg Equipment. The company manufactures implants for joint replacement, trauma, and spinal surgeries, as well as surgical equipment, navigation systems, and patient handling devices. Domestic sales accounted for 66% of total revenue in the quarter.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $1,320.9 million | $1,202.5 million |
| Gross Profit | $868.0 million (65.7% margin) | $772.5 million (64.2% margin) |
| Operating Income | $222.1 million | $236.4 million |
| Net Earnings | $147.5 million | $166.7 million |
| Diluted EPS | $0.36 | $0.41 |
| Operating Cash Flow | $20.7 million | $26.4 million |
| Cash & Cash Equivalents | $198.4 million | $491.2 million (Dec 31, 2005) |
| Marketable Securities | $675.7 million | $565.3 million (Dec 31, 2005) |
| Total Debt (Current + Long-Term) | $137.4 million | $231.6 million (Dec 31, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year, driven by an 11% increase in unit volume and product mix, partially offset by a 2% unfavorable impact from foreign currency exchange rates.
- Profitability Decline: Net earnings decreased 12% to $147.5 million. This decline was primarily due to a one-time charge of $52.7 million for purchased in-process research and development (IPR&D) related to the acquisition of Sightline Technologies Ltd.
- Adjusted Performance: Excluding the $52.7 million IPR&D charge, adjusted net earnings were $200.2 million, representing a 20% increase over the prior year.
- Accounting Change: The company adopted FASB Statement No. 123 (revised) effective January 1, 2006, requiring the recognition of stock-based compensation expense. This reduced operating income by $14.8 million and net earnings by $9.6 million for the quarter.
- Segment Performance:
- Orthopaedic Implants: Sales increased 7% (11% constant currency), with strong growth in knees, trauma, and spine products.
- MedSurg Equipment: Sales increased 16% (17% constant currency), driven by surgical equipment, navigation systems, and endoscopic products.
Guidance, Outlook, and Risks
- 2006 Outlook: Management projects diluted net earnings per share of $1.89 for 2006, a 20.4% increase over 2005. Adjusted diluted EPS is projected at $2.02 (21.0% increase).
- Sales Forecast: Net sales are expected to grow 11% to 14% in 2006. Excluding foreign currency impacts, growth is expected to be 12% to 15%.
- Foreign Currency: The company anticipates an unfavorable impact of 1% to 2% on net sales for the remainder of 2006 if exchange rates hold near recent levels.
- Acquisition Milestones: The Sightline acquisition includes potential milestone payments of up to $90.0 million, with the first payment not expected before 2007.
- Risks and Contingencies:
- Legal Proceedings: The company is cooperating with Department of Justice investigations regarding billing practices of its Physiotherapy Associates subsidiary and consulting contracts with orthopedic surgeons.
- Market Risks: Pricing pressures in the U.S., Japan, and other markets; regulatory actions; and reimbursement level changes.
- Operational Risks: Integration of acquired businesses (Sightline) and implementation of new ERP systems.
Investor Verification Checklist
- One-Time Charges: Verify the impact of the $52.7 million IPR&D charge on the Sightline acquisition and confirm the non-deductibility of this charge for tax purposes.
- Accounting Transition: Review the restatement of prior periods due to the adoption of FASB 123(R) and its effect on share-based compensation expense.
- Cash Flow Dynamics: Analyze the decrease in operating cash flow ($20.7M vs $26.4M) driven by increases in accounts receivable and inventory levels.
- Legal Exposure: Monitor the status of the Department of Justice investigations regarding billing practices and surgeon remuneration agreements.
- Foreign Currency Sensitivity: Assess the potential impact of currency fluctuations on the 2006 sales guidance, particularly given the 34% international revenue mix.